Heart failure patients experience exercise intolerance and functional limitation every day. While the targeting of functional capacity is an important unmet need, this study found that the change in peak oxygen uptake did not differ between patients taking omecamtiv mecarbil and placebo.

How do current guideline-directed medical therapies for heart failure impact exercise capacity? How does omecamtive mecarbil differ from other heart failure pharmacotherapies?

In this interview, Gregory Lewis, MD and Jeroen J. Bax PhD, MD, FACC, with Ioannis Mastoris, MD, MPHcand, discuss Late Breaker: METEORIC-HF: The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic HFrEF.